Investigation Report on China's Gliclazide Market, 2018-2022


Description
The overweight population and the incidence of type 2 diabetes are growing in China as the economy develops, the population ages, and the lifestyle changes. The number of people with type 2 diabetes exceeded 110 million at the end of 2017, and is still rising. 
Taken by mouth, Gliclazide is a second-generation sulfonylurea to treat diabetes by stimulating insulin secretion from pancreatic ?-cells. It can protect pancreatic ?-cells from the apoptosis caused by hyperglycemia, and prevent atherosclerosis (build-up of fatty deposits in the arteries) caused by type 2 diabetes. 
Developed by French company Servier, Gliclazide (trade name: Diamicron) was first launched in France in 1972, and entered China in the 1980s. In China, at least 200,000 people with type 2 diabetes are taking Gliclazide every year. 
In 1987, Tianjin Huajin Pharmaceutical Factory (now known as Tianjin Huajin Pharmaceutical Co., Ltd.) started cooperating with Servier and Tianjin Pharmaceutical Station to produce Gliclazide (Diamicron), a new drug to treat type 2 diabetes. With the support of Servier, the company has been taking the leading position on China's Gliclazide market. Also dominating the market are Servier and Servier (Tianjin) Pharmaceutical Co., Ltd., the joint venture of Servier and Tianjin Huajin Pharmaceutical Co., Ltd. 
According to CRI, the sales value of Gliclazide kept rising after the drug entered China, and exceeded CNY 200 million in 2017. It is expected that China's Gliclazide market will continue to grow as the incidence of type 2 diabetes rises.
Table of Contents
1 Relevant Concepts of Gliclazide
1.1 Indications for Gliclazide
1.2 Development History of Gliclazide in China
1.3 Governmental Approval of Gliclazide in China

2 Sales of Gliclazide in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Gliclazide by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis on Major Gliclazide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Gliclazide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Servier
3.2.1 Enterprise Profile
3.2.2 Sales of Servier's Gliclazide in China
3.3 Servier (Tianjin) Pharmaceutical Co., Ltd. 
3.4 Tianjin Huajin Pharmaceutical Co. Ltd. 
3.5 Nanchang Helioeast Pharmaceutical Co., Ltd. 
3.6 Guilin Hwasun Pharmaceutical Co., Ltd. 

4 Prices of Gliclazide in China, 2017-2018
4.1 Servier (Diamicron)
4.2 Servier (Tianjin) Pharmaceutical Co., Ltd. (Diamicron)
4.3 Tianjin Huajin Pharmaceutical Co. Ltd. (Diamicron)
4.4 Nanchang Helioeast Pharmaceutical Co., Ltd. (Hongxuyang)
4.5 Guilin Hwasun Pharmaceutical Co., Ltd. (Xieerping)

5 Prospect of China's Gliclazide Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Sales of Gliclazide in China, 2013-2017
Chart Sales Value of Gliclazide in Parts of China, 2013-2017
Chart Sales Volume of Gliclazide in China, 2013-2017
Chart Sales Value of Gliclazide Tablets in China, 2013-2017
Chart Sales Value of Gliclazide Capsules in China, 2013-2017
Chart Market Share of Top 5 Gliclazide Manufacturers by Sales Value in China, 2013-2017
Chart Profile of Servier
Chart Sales Value of Servier's Gliclazide in China, 2013-2017
Chart Sales Value of Servier (Tianjin) Pharmaceutical Co., Ltd.'s Gliclazide in China, 2013-2017
Chart Sales Value of Servier Tianjin Huajin Pharmaceutical Co. Ltd.'s Gliclazide in China, 2013-2017
Chart Prices of Servier's Gliclazide in Parts of China, 2017-2018
Chart Prices of Servier (Tianjin) Pharmaceutical Co., Ltd.'s Gliclazide in Parts of China, 2017-2018
Chart Prices of Tianjin Huajin Pharmaceutical Co. Ltd.'s Gliclazide in Parts of China, 2017-2018
Chart Governmental Approval of Gliclazide in China
Chart Forecast on Sales Value of Gliclazide in China, 2018-2012


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Finasteride Market, 2019-2023

Description The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases w...

Investigation Report on China's Prothrombin Complex Concentrate (PCC) Market, 2019-2023

Description Hemophilia is an X-linked recessive hemorrhagic disease. It is classified into hemophilia A, a deficiency in clotting factor VIII and hemophilia B, a deficiency in clotting factor IX. Both hemophilia A and hemophilia B are caused by gene ...

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

Description In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver...

Investigation Report on China's Pegaspargase Market, 2019-2023

Description According to the data released by China?s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 ol...

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

New Pharmaceuticals and Healthcare Reports

Publisher: China Research and Intelligence